Predictors of drusen reduction after subthreshold infrared (810 nm) diode laser macular grid photocoagulation for nonexudative age-related macular degeneration

Rodanant, Nuttawut; Friberg, Thomas R.; Cheng, Lingyun; Aurora, Ajay; Bartsch, Dirk-Uwe; Toyoguchi, Mitsuko; Corbin, Patricia; El-Bradey, Mohamed H; Freeman, William R.

doi:10.1016/s0002-9394(02)01691-4

Cited by 42 publications

(21 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[8][9][10][11][12][13] These trials confirmed the anecdotal observations that laser photocoagulation to the macula caused the disappearance of drusen. Color fundus imaging confirmed these observations.…”

Section: Introductionsupporting

confidence: 69%

Change in Drusen Volume as a Novel Clinical Trial Endpoint for the Study of Complement Inhibition in Age-related Macular Degeneration

Filho¹,

Yehoshua²,

Gregori³

et al. 2014

Ophthalmic Surg Lasers Imaging Retina

View full text Add to dashboard Cite

BACKGROUND AND OBJECTIVE:To evaluate the change in drusen volume following treatment with eculizumab, a systemic inhibitor of complement component 5. PATIENTS AND METHODS:Single-center, prospective, randomized, double-masked clinical trial. Patients were randomized 2:1 to receive intravenous eculizumab or placebo over 26 weeks. Main outcome measure: decrease in drusen volume of at least 50% at 26-week follow-up. RESULTS:Mean drusen cube root volumes were 0.49 mm and 0.47 mm (P = .64) at baseline and 0.51 mm and 0.42 mm (P = .17) at 26 weeks in the eculizumab and placebo groups, respectively. In the placebo group, one eye had a decrease in drusen volume of at least 50% and two eyes developed neovascularization through 26 weeks. CONCLUSION:Systemic complement inhibition with eculizumab did not significantly reduce drusen volume. Drusen growth was dependent on the number of complement at-risk alleles. Future trials should consider the use of a composite clinical trial endpoint in which efficacy is defined by the treatment's ability to prevent drusen growth, neovascularization, and the formation of geographic atrophy over 1 year.

show abstract

Section: Introductionsupporting

confidence: 69%

Change in Drusen Volume as a Novel Clinical Trial Endpoint for the Study of Complement Inhibition in Age-related Macular Degeneration

Filho¹,

Yehoshua²,

Gregori³

et al. 2014

Ophthalmic Surg Lasers Imaging Retina

View full text Add to dashboard Cite

show abstract

“…Over the course of the 3-year follow-up, the increased incidence of CNV in the laser-treated fellow eyes was maintained but there was no significant difference in vision loss. 59,60 The recently reported 3-year data on the bilateral arm study found no significant difference in the incidence of CNV in laser-treated or control eyes but did find a significant reduction in drusen in the treated eyes. In one subgroup of patients with bilateral drusen and with a baseline vision in the 20/32 to 20/63 range, the authors reported a small therapeutic effect on vision.…”

Section: ' Prophylactic Treatmentmentioning

confidence: 93%

“…3). 59,60 The PTAMD reported drusen reduction associated with laser treatment in the group with bilateral drusen. However, like the CNVPT Fellow Eye Study, the 6-month results of the PTAMD fellow eye trial showed an increased incidence of CNV and worsening of visual acuity in the laser-treated eyes.…”

Section: ' Prophylactic Treatmentmentioning

confidence: 99%

Thermal Laser Treatment in AMD: Therapeutic and Prophylactic

Cukras¹,

Fine²

2007

International Ophthalmology Clinics

View full text Add to dashboard Cite

“…Several large trials in the 2000s investigated the efficacy of the subthreshold laser in early AMD and consistently found that laser induced drusen regression, but did not improve outcomes, and in one large study even increased the risk of developing choroidal neovascularization. 26,68,69 The study was stopped prematurely and they concluded that the use of subthreshold laser was not recommended. 26 The subthreshold laser used in these studies was not micropulsed.…”

Section: Age-related Macular Degeneration: Low-quality Evidence Of Efmentioning

confidence: 99%

Subthreshold Diode Micropulse Laser: A Review

Brader

Young

2016

Seminars in Ophthalmology

View full text Add to dashboard Cite

The subthreshold diode micropulse laser is a form of non-damaging thermal laser therapy which has shown efficacy in multiple retinal conditions. The purpose of this article is to review the use of subthreshold diode micropulse laser as an emerging treatment modality for the treatment of retinal disease. The proposed mechanisms of action, safety, efficacy, recommended laser treatment parameters, and clinical applications for which the use of subthreshold diode micropulse laser has been studied will be reviewed.

show abstract

Predictors of drusen reduction after subthreshold infrared (810 nm) diode laser macular grid photocoagulation for nonexudative age-related macular degeneration

Cited by 42 publications

References 26 publications

Change in Drusen Volume as a Novel Clinical Trial Endpoint for the Study of Complement Inhibition in Age-related Macular Degeneration

Change in Drusen Volume as a Novel Clinical Trial Endpoint for the Study of Complement Inhibition in Age-related Macular Degeneration

Thermal Laser Treatment in AMD: Therapeutic and Prophylactic

Subthreshold Diode Micropulse Laser: A Review

Contact Info

Product

Resources

About